Skip to content

Replimune Group REPL Total Current Liabilities

Total Current Liabilities at other companies

Amgen logo
AmgenAMGN
$24.96B+8.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.11B+43.2%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$26.51M-39.2%
Immunome logo
ImmunomeIMNM
$27.41M-11.0%
CG Oncology logo
CG OncologyCGON
$35.22M+55.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
$26.66M+4.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total current liabilities?
Replimune Group (REPL) reported total current liabilities of $50.09M in Q4 2025.
How has Replimune Group's total current liabilities changed year-over-year?
Replimune Group's total current liabilities increased by 4.6% year-over-year, from $47.89M to $50.09M.
What is the long-term trend for Replimune Group's total current liabilities?
Over 4 years (2021 to 2025), Replimune Group's total current liabilities has grown at a 43.9% compound annual growth rate (CAGR), from $14.55M to $62.36M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.